SCHEDULE: Redmile Group Adjusts Atara Biotherapeutics Stake

Redmile Group, LLC and its affiliates have updated their Schedule 13D filing to reflect changes in beneficial ownership of Atara Biotherapeutics, Inc. following the exercise of pre-funded warrants.

Summary

• Redmile Group, LLC and its associated entities (Redmile Biopharma Investments II, L.P. and Redmile Strategic Long Only Trading Sub, Ltd.) have filed an amendment to their Schedule 13D concerning their holdings in Atara Biotherapeutics, Inc.
• The filing reports the exercise of pre-funded warrants, which resulted in a cashless exercise where some shares were withheld for exercise costs and the remainder were issued.
• Following the warrant exercise on July 16, 2026, Redmile Long Only ceased to be a 5% beneficial owner on July 22, 2026.
• The total beneficial ownership for all reporting persons is now 950,994 shares, representing 9.9% of the outstanding common stock.
• This ownership is comprised of directly held shares and shares issuable upon exercise of remaining warrants, subject to a 9.99% beneficial ownership limitation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It represents a routine adjustment of an investment position through warrant exercise rather than a significant strategic shift or new development.

Positives

• Redmile Group has actively managed its investment in Atara Biotherapeutics, exercising warrants to potentially increase its stake.
• The exercise of warrants and subsequent share issuance indicates a strategic move by Redmile to adjust its position in the company.
• The total beneficial ownership of 9.9% suggests a significant, though not controlling, stake in the company.

Negatives

• The cashless exercise means that some shares were used to cover the exercise price, reducing the net increase in shares held.
• The beneficial ownership is capped at 9.99%, limiting the potential for further increases in ownership through warrant exercise without triggering additional disclosure requirements or potential regulatory scrutiny.

Risks

• The beneficial ownership limitation of 9.99% restricts the maximum number of shares that can be acquired through warrant exercise, potentially limiting future strategic flexibility.
• The filing does not detail the specific reasons for the warrant exercise, which could be related to market conditions, company performance, or strategic shifts.

Future Outlook

The filing indicates that Redmile Funds hold warrants that could be exercised into an additional 3,217,632 shares of common stock, subject to the 9.99% beneficial ownership limitation. This suggests potential for further adjustments to their stake in Atara Biotherapeutics.

Management Comments

• Redmile Group, LLC, as the investment manager, may be deemed to beneficially own the securities held by the Redmile Funds.
• Jeremy Green, as the principal of Redmile Group, LLC, may also be deemed to beneficially own these securities.
• Redmile Group, LLC and Jeremy Green each disclaim beneficial ownership except to the extent of their pecuniary interest.

Industry Context

StockSavvy.ai notes that significant stake adjustments by institutional investors like Redmile Group, particularly in the biotechnology sector, often signal evolving views on a company's pipeline, clinical trial progress, or market positioning. The exercise of warrants suggests a belief in the company's future value, tempered by the 9.99% ownership cap.

Comparison to Industry Standards

• The 9.9% beneficial ownership held by Redmile Group is a substantial stake, often seen in activist or strategic investor positions within the biotechnology sector.
• Companies like Atara Biotherapeutics, which are often in development stages, attract significant interest from specialized investment funds that may hold similar ownership percentages in peer companies.
• The use of cashless warrant exercises is a common financial maneuver in the industry to manage capital and exercise costs while increasing equity exposure.

Stakeholder Impact

• Shareholders: The adjustment in beneficial ownership by a significant investor like Redmile Group may influence market perception and trading activity.
• Management: The increased stake by Redmile Group could signal their continued interest and potential influence on corporate strategy.
• Creditors: No direct impact is indicated, as the filing concerns equity ownership.

Next Steps

• Redmile Funds may continue to exercise remaining warrants, subject to the 9.99% beneficial ownership limitation.
• Further amendments to Schedule 13D will be required if beneficial ownership changes significantly.

Key Dates

Keywords

Atara Biotherapeutics, Redmile Group, Schedule 13D, Beneficial Ownership, Warrant Exercise, Investment Management, Biotechnology, Healthcare